Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2023

Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2023 – By Drug Class (Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes), By Treatment (Medication, Therapy, Other Treatments), By Drug Type (Branded, Generic), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels), By End-User (Hospitals, Research Institutes, Specialty Clinics) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : August 2023 | Delivery Time: 2-3 business days | Format :

Need assistance or more information before the purchase?

Enquire Before Buying
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2023

Proud Members Of

Chemotherapy induced peripheral neuropathy (CIPN) refers to a set of symptoms and complications that can develop because of certain chemotherapy drugs used in the treatment of cancer. It is a type of peripheral neuropathy, which involves damage or dysfunction of the peripheral nerves that connect the brain and spinal cord to the rest of the body.

The main drug classes of chemotherapy induced peripheral neuropathy treatment are nerve protective therapy, anti-inflammatory therapy, neurotransmitter-based therapy, antioxidant, and others. Nerve protective therapy refers to treatments or interventions aimed at preserving or safeguarding the health and function of nerves. Nerve protective therapy is utilized in the management of chemotherapy-induced peripheral neuropathy to help preserve nerve function and alleviate symptoms. The various treatments include medication, therapy, and others and the types of drugs are branded and generic. The chemotherapy induced peripheral neuropathy treatment drugs are sold at hospital pharmacies, retail pharmacies, online pharmacies, and others and the end-users include hospitals, research institutes, and specialty clinics.

The global chemotherapy induced peripheral neuropathy treatment market is segmented -

1) By Drug Class: Nerve Protective Therapy, Anti-Inflammatory Therapy, Neurotransmitter Based Therapy, Antioxidant, Other Drug Classes

2) By Treatment: Medication, Therapy, Other Treatments

3) By Drug Type: Branded, Generic

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Research Institutes, Specialty Clinics

The global chemotherapy induced peripheral neuropathy market size is expected to grow from $1.43 billion in 2022 to $1.54 billion in 2023 at a compound annual growth rate (CAGR) of 7.12%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of chemotherapy induced peripheral neuropathy market is expected to reach $2.06 billion in 2027 at a CAGR of 7.57%.

The increasing prevalence of cancer is expected to propel the growth of the chemotherapy-induced peripheral neuropathy treatment market going forward. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells in the body. Chemotherapy-induced peripheral neuropathy is a potential side effect of certain chemotherapy drugs used in the treatment of cancer. The chemotherapy-induced peripheral neuropathy treatment market is subjected to grow as there is a rise of cancer cases globally. For instance, in 2023, according to the report published by the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated new cases of liver cancer in females diagnosed in the United States increased from 12,660 in 2022 to 13,230 in 2023. Therefore, the increasing prevalence of cancers driving the growth of the chemotherapy-induced peripheral neuropathy treatment market.

Major players in the chemotherapy induced peripheral neuropathy treatment market are Sanofi SA, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical Company, Amgen Inc., Asahi Kasei Pharma Corporation, Toray Industries, Vertex Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., BioMérieux SA, Jazz Pharmaceuticals Inc., WEX Pharmaceuticals Inc., Quidel Corporation, Laboratories Dr. Esteve S.A. (ESTEVE), Genentech Inc., MediciNova Inc., ChromaDex Corp, WinSanTor Inc., Solasia Pharma K.K., NeuroMetrix Inc., Nemus Bioscience Inc., Aphios Corporation, Kineta Inc., DARA BioSciences Inc., Aptinyx Inc., Apexian Pharmaceuticals Inc., and Krenitsky Pharmaceuticals Inc.

Product Innovation is the key trend gaining popularity in the chemotherapy-induced peripheral neuropathy treatment market. Major companies involved in the chemotherapy-induced peripheral neuropathy treatment market are focused on innovating new products to improve their observation power and sustain their position in the market.in March 2023, AlgoTx, a clinical-stage company specializing in complex pain management, disclosed the FDA's approval of the Investigational New Drug Application (IND) for ATX01, their Phase 2 first-in-class candidate. This innovative treatment is intended for individuals with erythromelalgia. Meanwhile, the first patients in the "ATX01 for the Pain of Chemotherapy" (ACT) study of chemotherapy-induced peripheral neuropathy (CIPN) have been randomized. The FDA has given both programs fast-track designation.

In September 2021, Novaremed AG a Switzerland-based biopharmaceutical company acquired Metys Pharmaceuticals AG for an undisclosed amount. Through this acquisition, Novaremed AG expands its pipeline to target a wider segment of neuropathic pain indications, by adding chemotherapy-induced peripheral neuropathy (CIPN) to its current focus on painful diabetic peripheral neuropathy (PDPN). Metys Pharmaceuticals AG is a Switzerland-based pharmaceutical company that focuses on the development and commercialization of innovative therapies for the treatment of various medical conditions.

North America was the largest region in the chemotherapy induced peripheral neuropathy treatment market in 2022. Asia-Pacific and Europe are expected to be the fastest-growing regions in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chemotherapy induced peripheral neuropathy treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chemotherapy induced peripheral neuropathy treatment market consists of sales of pharmaceutical drugs prescribed to alleviate chemotherapy-induced peripheral neuropathy symptoms. These drugs include pain relievers, antidepressants, anticonvulsants, and topical creams. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The chemotherapy induced peripheral neuropathy treatment market research report is one of a series of new reports from The Business Research Company that provides chemotherapy induced peripheral neuropathy treatment market statistics, including the chemotherapy induced peripheral neuropathy treatment industry's global market size, regional shares, competitors with an chemotherapy induced peripheral neuropathy treatment market share, detailed chemotherapy induced peripheral neuropathy treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the chemotherapy induced peripheral neuropathy treatment industry. This chemotherapy induced peripheral neuropathy treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Executive Summary

    2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Characteristics

    3. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends And Strategies

    4. Chemotherapy Induced Peripheral Neuropathy Treatment Market - Macro Economic Scenario

    4.1. Impact Of High Inflation On Online Therapy Services Market

    4.2. Ukraine-Russia War Impact On Online Therapy Services Market

    4.3. COVID-19 Impact On Online Therapy Services Market

    5.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Historic Market Size and Growth, 2017 - 2022, Value ($ Billion)

    5.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecast Market Size and Growth, 2022 - 2027, 2032F, Value ($ Billion)

    5.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers and Restraints

    5.3.1. Drivers Of The Market

    5.3.2. Restraints Of The Market

    6. Chemotherapy Induced Peripheral Neuropathy Treatment Market Segmentation

    6.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Nerve Protective Therapy

    Anti-Inflammatory Therapy

    Neurotransmitter Based Therapy

    Antioxidant

    Other Drug Classes

    6.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Medication

    Therapy

    Other Treatments

    6.3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Branded

    Generic

    6.4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacies

    Other Distribution Channels

    6.5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospitals

    Research Institutes

    Specialty Clinics

    7. Chemotherapy Induced Peripheral Neuropathy Treatment Market Regional And Country Analysis

    7.1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    8.1. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.4. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    9.1. China Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview  

    9.2. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.4. China Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    10.1. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.3. India Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    11.1. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.3. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    12.1. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.3. Australia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    13.1. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.3. Indonesia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    14.1. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.3. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    15.1. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    15.2. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.4. Western Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    16.1. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.3. UK Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    17.1. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.3. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    18.5. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.6. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.7. France Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    19.9. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.10. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.11. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    20.13. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.14. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.15. Spain Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    21.1. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    21.2. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.4. Eastern Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    22.1. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.2. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    23.1. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    23.2. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.4. North America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    24.1. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    24.2. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.3. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.4. USA Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    25.1. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    25.2. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.4. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    26.1. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    26.2. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.4. South America Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    27.1. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27.2. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27.3. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    28. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    28.1. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    28.2. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    28.3. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    28.4. Middle East Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    29. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market  

    29.1. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Overview

    29.2. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    29.3. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    29.4. Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    30. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape And Company Profiles

    30.1. Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Landscape

    30.2. Chemotherapy Induced Peripheral Neuropathy Treatment Market Company Profiles

    30.2.1. Sanofi SA

    30.2.1.1. Overview

    30.2.1.2. Products and Services

    30.2.1.3. Strategy

    30.2.1.4. Financial Performance

    30.2.2. Bristol Myers Squibb

    30.2.2.1. Overview

    30.2.2.2. Products and Services

    30.2.2.3. Strategy

    30.2.2.4. Financial Performance

    30.2.3. Abbott Laboratories

    30.2.3.1. Overview

    30.2.3.2. Products and Services

    30.2.3.3. Strategy

    30.2.3.4. Financial Performance

    30.2.4. Takeda Pharmaceutical Company

    30.2.4.1. Overview

    30.2.4.2. Products and Services

    30.2.4.3. Strategy

    30.2.4.4. Financial Performance

    30.2.5. Amgen Inc.

    30.2.5.1. Overview

    30.2.5.2. Products and Services

    30.2.5.3. Strategy

    30.2.5.4. Financial Performance

    31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Other Major And Innovative Companies

    31.1. Asahi Kasei Pharma Corporation

    31.2. Toray Industries 

    31.3. Vertex Pharmaceuticals Inc.

    31.4. Alexion Pharmaceuticals Inc.

    31.5. BioMérieux SA

    31.6. Jazz Pharmaceuticals Inc.

    31.7. WEX Pharmaceuticals Inc.

    31.8. Quidel Corporation

    31.9. Laboratorios Dr. Esteve S.A. (ESTEVE)

    31.10. Genentech Inc.

    31.11. MediciNova Inc.

    31.12. ChromaDex Corp

    31.13. WinSanTor Inc.

    31.14. Solasia Pharma K.K.

    31.15. NeuroMetrix Inc.

    32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Benchmarking

    33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Competitive Dashboard

    34. Key Mergers And Acquisitions In The Chemotherapy Induced Peripheral Neuropathy Treatment Market

    35. Chemotherapy Induced Peripheral Neuropathy Treatment Market Future Outlook and Potential Analysis

    35.1 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2027 - Countries Offering Most New Opportunities

    35.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2027 - Segments Offering Most New Opportunities

    35.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market In 2027 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 48: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 49: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 50: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 51: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 52: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 53: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 54: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 55: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 56: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 57: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 58: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 59: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 60: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 61: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 62: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 63: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 64: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 65: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 66: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 67: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 68: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 69: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 70: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 71: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 72: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 73: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 74: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 75: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 76: Sanofi SA Financial Performance
  • Table 77: Bristol Myers Squibb Financial Performance
  • Table 78: Abbott Laboratories Financial Performance
  • Table 79: Takeda Pharmaceutical Company Financial Performance
  • Table 80: Amgen Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Treatment, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Global Chemotherapy Induced Peripheral Neuropathy Treatment Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: Asia-Pacific, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: China, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: India, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: Japan, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Australia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: Indonesia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: South Korea, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: Western Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: UK, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: Germany, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: France, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Italy, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 48: Spain, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 49: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 50: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 51: Eastern Europe, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 52: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 53: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 54: Russia, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 55: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 56: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 57: North America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 58: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 59: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 60: USA, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 61: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 62: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 63: Canada, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 64: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 65: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 66: South America, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 67: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 68: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 69: Brazil, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 70: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 71: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 72: Middle East, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 73: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 74: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 75: Africa, Chemotherapy Induced Peripheral Neuropathy Treatment Market, Segmentation By End-User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 76: Sanofi SA Financial Performance
  • Figure 77: Bristol Myers Squibb Financial Performance
  • Figure 78: Abbott Laboratories Financial Performance
  • Figure 79: Takeda Pharmaceutical Company Financial Performance
  • Figure 80: Amgen Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report